Top

Published in:

01-01-2007

Evaluation of Serum Amyloid A as a Biomarker for Gastric Cancer

Authors: De-Chuan Chan, MD, Cheng-Jueng Chen, MD, Heng-Cheng Chu, MD, Wei-Kuo Chang, MD, Jyh-Cherng Yu, MD, Yu-Ju Chen, Li-Li Wen, Su-Ching Huang, Chih-Hung Ku, Yao-Chi Liu, MD, Jenn-Han Chen, MD

Published in: Annals of Surgical Oncology | Issue 1/2007

Abstract

Background

Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans.

Methods

Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides.

Results

The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P < .05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren’s histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P < .0001) and lymph node status (P < .05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P < .05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells.

Conclusions

These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up.

Stadtlander CT, Waterbor JW. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis 1999; 20:2195–208PubMedCrossRef

Health and Vital Statistics. Taipei: Department of Health, Executive Yuan, Republic of China, 1997

Collard JM, Malaise J, Mabrut JY, et al. Skeletonizing. En-bloc gastrectomy for adenocarcinoma in Caucasian patients. Gastric Cancer 2003; 6:210–16PubMedCrossRef

Juan HF, Chen JH, Hsu WT, et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: From mouse to human. Proteomics 2004; 4:2766–775PubMedCrossRef

Sheu LF, Chen A, Wei YH, et al. Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis. Am J Pathol 1998; 152:63–74PubMed

Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999; 37:381–8PubMedCrossRef

Biran H, Friedman N, Neumann PM, et al. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 1986; 39:794–7PubMedCrossRef

Kimura M, Tomita Y, Imai T, et al. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 2001; 92(8):2072–5PubMedCrossRef

Glojnaric I, Casl MT, Simic D, et al. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 2001; 39(2):129–33PubMedCrossRef

10.

Kaneti J, Winikoff Y, Zimlichman S, et al. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 1984; 12(5):239–41PubMedCrossRef

11.

Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004; 10(1 Pt 1):43–52PubMedCrossRef

12.

O’Hanlon DM, Lynch J, Cormican M, Given HF. The acute phase response in breast carcinoma. Anticancer Res 2002; 22:1289–93PubMed

13.

Rosenthal CJ, Sullivan LM. Serum amyloid A to monitor cancer dissemination. Ann Intern Med 1979; 91:383–90PubMed

14.

Japanese Research Society for Gastric Cancer. (1993). The General Rules for the Gastric Cancer Study. 12th edn. Tokyo: Kanehara, pp 30–3

15.

Sobin LH, Wittekind CH. (1997). International Union Against Cancer (UICC): TNM classification of malignant tumors, 5th edn. New York: John Wiley.

16.

Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64:31–49PubMed

17.

Juan HF, Lin JY, Chang WH, et al. Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatics analytical methods. Electrophoresis 2002; 23:2490–504PubMedCrossRef

18.

d’Eril GM, Anesi A, Maggiore M, et al. Biological variation of serum amyloid A in healthy subjects. Clin Chem 2001; 47:1498–9PubMed

19.

Shimizu N, Wakatsuki T, Murakami A. Carcinoembryonic antigen in gastric cancer patients. Oncology 1987; 44:240–4PubMedCrossRef

20.

Nakane Y, Okamura S, Akehira K, et al. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. Cancer 1994; 73:2703–8PubMedCrossRef

21.

Koga T, Kano T, Souda K. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg 1987; 17:342–7PubMedCrossRef

22.

Sakamoto K, Haga Y, Yoshimura R, et al. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut 1987; 28:323–9PubMedCrossRef

23.

Marrelli D, Roviello F, De Stefano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999; 57:55–62PubMedCrossRef

24.

Safi F, Kuhns V, Beger HG. Comparison of CA72-4, CA19-9 and CEA in the diagnosis and monitoring of gastric cancer. Int J Biol Markers 1995; 10:100–6PubMed

25.

Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127–31PubMedCrossRef

26.

Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302:1302–5PubMedCrossRef

27.

Hansen S, Melby KK, Aase S, Jellium E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia cancer. Scand J Gastroenterol 1999; 4:353–60CrossRef

28.

Delanghe JR, Langlois MR, De Bacquer D, Mak R, Capel P, Van Renterghem L, De Backer G. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis 2002; 160(2): 471–6PubMedCrossRef

29.

Hagihara K, Nishikawa T, Isobe T, et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314(2):363–9PubMedCrossRef

30.

Galizia G, Lieto E, De Vita F, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: Relationship with radicality and outcome. J Interferon Cytokine Res 2002; 22:473–82PubMedCrossRef

31.

Yamaoka Y, Kodama T, Kita M, et al. Relation between cytokines and Helicobacter pylori in gastric cancer. Helicobacter 2001; 6:116–24PubMedCrossRef

32.

De Vita F, Romano C, Orditura M, et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21:45–52PubMedCrossRef

33.

Wu CW, Wang SR, Chao MF, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996; 91:1417–22PubMed

34.

Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumor necrosis factor-alpha in patients with gastric cancer. Cancer Lett 1995; 95:207–12PubMedCrossRef

35.

Tatsuno I, Nishikawa T, Sasano H, et al. Interleukin 6-producing gastric carcinoma with fever, hypergammaglobulinemia, and plasmacytosis in bone marrow. Gastroenterology 1994; 107:543–7PubMed

36.

Lin MT, Juan CY, Chang KJ, et al. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 2001; 22:1947–53PubMedCrossRef

37.

Ding SZ, Cho CH, Lam SK. Regulation of IL-6 production in human gastric epithelial cell line MKN-28. Cytokine 2000; 12:1129–35PubMedCrossRef

Title: Evaluation of Serum Amyloid A as a Biomarker for Gastric Cancer
Authors: De-Chuan Chan, MD
Cheng-Jueng Chen, MD
Heng-Cheng Chu, MD
Wei-Kuo Chang, MD
Jyh-Cherng Yu, MD
Yu-Ju Chen
Li-Li Wen
Su-Ching Huang
Chih-Hung Ku
Yao-Chi Liu, MD
Jenn-Han Chen, MD
Publication date: 01-01-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9091-z

At a glance: The STEP trials

Springer Medicine

Evaluation of Serum Amyloid A as a Biomarker for Gastric Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2007

Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma

Predictors for Patterns of Failure after Pancreaticoduodenectomy in Ampullary Cancer

Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery in Patients with Very Advanced Gastric Cancer

The 2003 Revised TNM Staging System for Breast Cancer: Results of Stage Re-classification on Survival and Future Comparisons among Stage Groups

Clinical Results on Intra-arterial Adjuvant Chemotherapy for Prevention of Liver Metastasis Following Curative Resection of Pancreatic Cancer

Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†